Actively Recruiting
A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis
Led by Pfizer · Updated on 2026-03-30
360
Participants Needed
34
Research Sites
111 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this real world non-interventional study is to learn about the effects of etrasimod as treatment for patients with moderate to severe ulcerative colitis. Patients will be treated according to standard of care and will only be included in the study if etrasimod is the best treatment choice according to the treating physician. Additionally, patients have to be between 18 and 65 years of age and should not have taken etrasimod in the past. All patients will be prescribed etrasimod according to standard of care. Assessments will be conducted according to standard of care with the exception of health questionnaires which will be completed by the patients online on their own device. The study duration is 52 weeks with 28 days of safety follow-up. Patients will visit their treating physician as they would if they were not enrolled in the study. During the study duration, patients will be asked to complete health questionnaires on a regular basis either on their mobile phone, tablet or computer. The effects of etrasimod will be analyzed for each patient comparing to their disease activity prior to the start of etrasimod.
CONDITIONS
Official Title
A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male and female patients 18 to less than 65 years of age at baseline
- Confirmed diagnosis of ulcerative colitis with moderately to severely active disease
- Prescribed etrasimod as per product label independently of study enrollment
- Signed and dated informed consent confirming understanding of the study
You will not qualify if you...
- Clinical findings that suggest Crohn's disease
- Severe extensive colitis with high risk of hospitalization or surgery within 12 weeks
- Evidence of acute severe ulcerative colitis, fulminant colitis, or toxic megacolon
- Having a stoma or planned ulcerative colitis surgery requiring hospitalization
- Previous exposure to etrasimod or participation in its clinical program
- Use of methotrexate, thiopurines, certain biologics, JAK inhibitors, or other S1P receptor modulators
- No access to or unwillingness to use a digital device with internet for health questionnaires
- Investigator site staff, Pfizer employees involved in the study, their supervisors, or family members
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 34 locations
1
Vancouver Coastal Health
Vancouver, British Columbia, Canada, V5Z 1M9
Not Yet Recruiting
2
Providence Health Care (PHC)
Vancouver, British Columbia, Canada, V6Z 2K5
Actively Recruiting
3
London Health Sciences Centre
London, Ontario, Canada, N6A5A5
Not Yet Recruiting
4
CHUM
Montreal, Quebec, Canada, H2X 3E4
Actively Recruiting
5
Montreal General Hospital
Montreal, Quebec, Canada, H3G 1A4
Not Yet Recruiting
6
Gastroenterologie OpernstraBe
Kassel, Hesse, Germany, 34117
Actively Recruiting
7
MVZ Gastroenterologie Aachen
Aachen, Germany, 52064
Actively Recruiting
8
Praxis Heil und Müller
Andernach, Germany, 56626
Actively Recruiting
9
MVZ für Gastroenterologie am Bayerischen Platz
Berlin, Germany, 10825
Actively Recruiting
10
Evangelisches Krankenhaus Kalk
Cologne, Germany, 51103
Actively Recruiting
11
MVZ Dachau
Dachau, Germany, 85221
Actively Recruiting
12
Interdisziplinares Crohn Colitis Centrum
Frankfurt am Main, Germany, 60594
Actively Recruiting
13
Facharztpraxis für Gastroenterologie
Grevenbroich, Germany, 41515
Actively Recruiting
14
Studiengesellschaft BSF UG.
Halle, Germany, 06108
Actively Recruiting
15
Praxis für Gasteroenterologie
Heidelberg, Germany, 69115
Actively Recruiting
16
Praxis für Gasteroenterologie Lübeck
Lübeck, Germany, 23560
Actively Recruiting
17
Klinikum Lüneburg
Lüneburg, Germany, 21339
Actively Recruiting
18
Internistische Praxengemeinschaft Oldenburg
Oldenburg, Germany, 10115
Actively Recruiting
19
Magen-Darm-Zentrum Remscheid
Remscheid, Germany, 42859
Actively Recruiting
20
CED am Rhein
Wesseling, Germany, 50389
Actively Recruiting
21
NHS Greater Glasgow and Clyde
Glasgow, Lanarkshire, United Kingdom, G4 0SF
Actively Recruiting
22
Nottingham University Hospitals NHS Trust, Queens Medical Centre
Nottingham, Nottinghamshire, United Kingdom, NG7 2UH
Actively Recruiting
23
Oxford University Hospitals NHS Foundation Trust
Oxford, Oxfordshire, United Kingdom, OX3 9DU
Actively Recruiting
24
Western General Hospital
Edinburgh, Scotland, United Kingdom, EH4 2XU
Actively Recruiting
25
Northern Care Alliance NHS Foundation Trust, Greater Manchester
Crumpsall, United Kingdom, M8 5RB
Actively Recruiting
26
Tunbridge Wells Hospital
Kent, United Kingdom, TN2 4QJ
Actively Recruiting
27
Barts Health NHS Trust, The Royal London Hospital
London, United Kingdom, E1 1BB
Actively Recruiting
28
St. Mark's Hospital
London, United Kingdom, HA1 3UJ
Actively Recruiting
29
University College London Hospital
London, United Kingdom, NW1 2PG
Actively Recruiting
30
St Thomas' Hospital - Guy's & St Thomas' NHS Foundation Trust
London, United Kingdom, SE1 7EH
Actively Recruiting
31
Kings College Hospital
London, United Kingdom, SE59RS
Actively Recruiting
32
St George's Hospital - St George's Healthcare Nhs Trust
London, United Kingdom, SW17 0QT
Actively Recruiting
33
Imperial College Healthcare NHS
London, United Kingdom, W2 1PG
Actively Recruiting
34
Southampton University Hospitals NHS Trust
Southampton, United Kingdom, SO16 6YD
Actively Recruiting
Research Team
P
Pfizer CT.gov Call Center
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here